- Current report filing (8-K)
December 17 2009 - 11:53AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 17, 2009
NEUROBIOLOGICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-23280
|
|
94-3049219
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
2000 Powell Street, Suite 800, Emeryville,
California
|
|
94608
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(510) 595-6000
|
NOT APPLICABLE
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 8.01. Other Events.
On December 17, 2009, Neurobiological Technologies, Inc. (the
Company
) filed a Certificate of Dissolution with
the Secretary of State of the State of Delaware. The Company also closed its stock transfer books, effective
immediately prior to the opening of business on December 17, 2009. Both the filing of the Certificate of Dissolution
and closing of its stock transfer books were completed in accordance with the previously announced plan of complete
liquidation and dissolution of the Company that was approved at a special meeting of the Companys stockholders on
October 27, 2009.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release of Neurobiological Technologies, Inc., dated December 17, 2009
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
Dated: December 17, 2009
|
|
|
|
NEUROBIOLOGICAL TECHNOLOGIES, INC.
|
|
|
By:
|
/s/ Matthew M. Loar
|
|
|
Matthew M. Loar
Vice President and Chief Financial Officer
|
3
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release of Neurobiological Technologies, Inc., dated December 17, 2009.
|
4
Neurobiological Technolo... (CE) (USOTC:NTII)
Historical Stock Chart
From Nov 2024 to Dec 2024
Neurobiological Technolo... (CE) (USOTC:NTII)
Historical Stock Chart
From Dec 2023 to Dec 2024